We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to ...

Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

Pressure may grow on companies to repatriate production, raising production costs and potentially medicine prices too.

In addition to this, Moody’s upgraded Merck & Co., Inc.’s senior unsecured revolving credit facility to Aa3 from A1, and the senior unsecured shelf ratings of both Merck & Co., Inc. and MSD ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

A class action lawsuit is brewing against Merck & Co. over claims of securities fraud, and investors aren’t exactly raising a ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") and reminds investors of the April 14, 2025 ...

Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") of a class action securities lawsuit.